<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318263</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A01767-46</org_study_id>
    <nct_id>NCT03318263</nct_id>
  </id_info>
  <brief_title>CIrCuLAting Dna ESr1 Gene Mutations Analysis</brief_title>
  <acronym>CICLADES</acronym>
  <official_title>Monitoring of ESR1, PIK3CA and AKT ctDNA Mutations During Real-life Followup of Patients With Metastatic Breast Cancer Treated With Aromatase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The estrogen-dependent nature of breast cancer was first reported in 1896 with the
      publication of George Beatson's observations on the regression of breast cancer following
      oophorectomy. Endocrine therapy, targeting ER either directly by selective estrogen receptor
      modulators (SERMs) and pure antagonists or indirectly by aromatase inhibitors (AIs) that
      block estrogen production, remains the mainstay of treatment of hormone-sensitive breast
      cancer in the adjuvant and metastatic settings.

      Intrinsic (de novo) and acquired endocrine resistance constitutes an important clinical
      challenge in the treatment of breast cancer and multiple mechanisms are suspected to underlie
      the emergence of endocrine resistance.

      The role of the estrogen receptor (ER), encoded by the ESR1 gene, in normal mammary gland
      development and the progression of breast cancer is well established. ESR1 mutations,
      occurring in 10 to 30% of ER-positive metastatic breast cancer resistant to AIs, lead to
      ligand-independent activation of the ER.

      For patients treated with AIs, monitoring of circulating tumour DNA (ctDNA) for ESR1, PIK3CA
      and AKT1 mutations could permit early detection of resistance to AIs as recently reported
      during 2016 American Society of Clinical Oncology (ASCO) meeting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of ESR1 mutations</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of PIK3CA and AKT1 mutations</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictors of progression free survival</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>next-generation sequencing (NGS)</intervention_name>
    <description>ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged 18 or older

          -  Histologically confirmed estrogen-receptor-positive, HER2-negative breast cancer

          -  Previously untreated metastatic (AJCC stage IV) or locoregionally advanced inoperable
             (AJCC stage III) breast cancer

          -  Indication to treat with AIs

          -  Exclusive endocrine monotherapy

          -  Informed consent explained to, understood by and signed by patient. Patient given copy
             of informed consent

        Exclusion Criteria:

          -  Tumour tissue sample not available for pathological review or correlative studies

          -  Chemotherapy or endocrine therapy for breast cancer within the last 12 months before
             inclusion

          -  Any concurrent severe and/or uncontrolled medical conditions which could compromise
             participation in the study

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MASSARD VINCENT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN JEAN LOUIS</last_name>
    <phone>00 33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES LAURINDA</last_name>
    <phone>00 33 3 83 59 84 87</phone>
    <email>f.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Claude Bernard</name>
      <address>
        <city>Metz</city>
        <zip>57070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GARDNER Miriam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LONGO Rafaelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'oncologie Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Célia BECUWE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SAVOYE Aude-Marie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PRULHIERE Karine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique de l'Orangerie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ACHILLE Mihaela, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TAZI Youssef, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BARHELEMY Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54509</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MASSARD VINCENT, MD</last_name>
      <email>v.massard@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estrogen-receptor-positive breast cancer</keyword>
  <keyword>aromatase inhibitor,</keyword>
  <keyword>ESR1,</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>AKT</keyword>
  <keyword>endocrine resistance</keyword>
  <keyword>circulating tumor DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

